treatment of psychotic disorders lucie bankovská motlová 7.10.2010
TRANSCRIPT
Treatment of psychotic disorders
Lucie Bankovská Motlová
7.10.2010
What is Psychosis?• Generic term• “Break with Reality”• Symptom or syndrome, not an illness• Caused by a variety of conditions that
affect the functioning of the brain.• Includes hallucinations, delusions and
thought disorder
Psychotic Disorders:
DSM-IV and ICD-10 Differences DSM-IV
• Schizophrenia• Schizophreniform disorder• Schizoaffective disorder• Delusional disorder• Brief psychotic disorder• Shared psychotic disorder• Psychotic disorder due to a
general medical condition• Substance-induced
psychotic disorder
ICD-10• Schizophrenia• Schizotypal disorder• Persistent delusional
disorders• Acute and transient
psychotic disorders• Induced delusional disorder• Schizoaffective disorders
Treatment of psychotic disorders
other
Psychosocial treatment
Pharmacotherapy
•Antipsychotics•Anxiolytics•Antidepressants•Anticholinergics
•Psychoeducation•Social skills training•Psychotherapy •Rehabilitation of cognitive function•Family intervention•Wellness programme
•Elektroconvulsive therapy•Transcranial magnetic stimulation
Treatment of psychotic symptoms
Antipsychotic medication
(„neuroleptics“)
Schizoaffectivedisorders
Schizophrenia
Acute psychotic disorders
Schizophreniphormdisorders
Toxic psychoses
PSYCHÓZYDOPAMINE
DOPAMIN
• Endogenous dopaminergic sensitization: PET
• Amphetamines intake = ↑↑↑ endogenous dopamin in schizophrenia patients in the acute phase, in comparison with healthy persons
• Relapse of schizophrenia = recurrence of hyperdopaminergic state in subcortical structures
• IMPLICATIONS FOR TREATMENT Chronic blockade of D2 receptors: blocking of sensitization processes
Laurelle 1999
Neurochemical sensitization in mesolimbic dopaminergic system
(studies in schizophrenia)
=
First and Second generation antipsychotics receptor profile
podle Stahla, 1999
Haloperidole and D2 receptor blockade
11C-Raclopride PET Scan
Coregistered MRI Scan
BeforeTreatment
Haloperidol2 mg/d (74% Occ.)
11C-Raclopride PET Scan
(Farde 1995)
5-HT2 and D2 receptor blockade
First generation antipsychotics
Generic name Product name Daily dose
chlorpromazine Plegomazin 200-600 (800)
levomepromazine Tisercin 50-400
thioridazine Thioridazin 100-600
periciazine Neuleptil 10-40
chlorprothixene Chlorprothixen 100-600
zuclopenthixol Cisordinol 20-60
perfenazine Perfenazin 16-64
prochlorperazine Prochlorperazin 20-80
tifluoperazine Stelazin 10-50
flupentixol Fluanxol 6-18
haloperidol Haloperidol 2,5-10
melperone Buronil 50-300
pimozid Orap 2-10
fluspiriliene Imap 2-10
penfluridol Semap 20-60
oxyprotepine Meclopin 5-20
First generation antipsychotics: Depot
Generic name Product name dose frequency
oxyprotepin decanoat Meclopin 12,5-75 3-4 weeks
haloperidol decanoat Haloperidol decanoate 12,5-75 4 weeks
fluspirilen Imap 2-10 5-7 days
flufenazin decanoat Moditen Depot 12,5-50 2-4 weeks
cis(Z)-flupentixol decanoat
Fluanxol Depot 20-60 2-4 weeks
zuclopenthixol decanoat Cisordinol Depot 100-400 2-4 weeks
zuclopenthixol acetat Cisordinol Acutard 50-150 2-3 days
Second generation antipsychotics
Generic name Product name Dosage (mg/day)
clozapine Leponex 200-600
olanzapine Zyprexa 10-20
quetiapine Seroquel 300-700
zotepine Zoleptil 100-300
risperidon Risperdal, Rispen 4-8
ziprasidon Zeldox 80-160
sulpirid Dogmatil, Prosulpin 400-1200
amisulprid Solian 400-1200
aripiprazole Abilify 10-30
paliperidone Invega 6-12
Second generation antipsychotics for
parenteral use Generic name Product name indication dosage
olanzapine Zyprexa Acute agitation 10 mg i.m.
ziprasidone Zeldox Acute agitation 10-20 mg i.m. (max. 40mg i.m./24 hodin).
risperidone Risperdal Consta Depot medication-long-term
Every 2 weeks
Advantages of Atypical Neuroleptics• Broader therapeutic spectrum
– therapeutic efficacy on • positive symptoms• refractory — residual
– reduction, prevention:• negative (deficit) syndrome• depressive symptoms• cognitive deficits
• No (fewer) side effects – objective: acute EPS, TD– subjective: dysphoric response
Side Effects of Antipsychotics
1. Effects of dopaminergic blockade
2. Effects of other receptors´blockade
Dopaminergic tracts
nigrostriatal
mesocortical
mesolimbic
tuberoinfundibular
Effects of dopaminergic blockade
Wanted effects:• blockade in mesolimbic
pathway:• - reduction of
psychotic symptoms• - relapse prevention
Unwanted effects:• blockade in
mesocortical pathway: apathy, lack of motivation
• blockade in tuberoinfundibular pathway: ↑ prolactin
• blockade in nigro-striatal pathway: extrapyramidal symptoms
Antipsychotics: nigrostriatal dopaminergic blockade effects
(Seem
an 1996)
Extrapyramidal side effects of antipsychotics
• Parkinsonism• Acute dystonia • Akathisia• Tardive dyskinesia
Video:Extrapyramidal syndromes
First and Second generation antipsychotics receptor profile
podle Stahla, 1999
Other side effects of antipsychotics
sleepeness low blood pressure dry mouth constipation
Sexual problems Weight gain Life threatening:Malignant
neuroleptic syndrome
Antipsychotics: Side EffectsAntipsychotics: Side Effects
• Neurological (Extrapyramidal) DA-blockNeurological (Extrapyramidal) DA-block
• Non-NeurologicalNon-Neurological • Histaminergic: Sedation, Wt gainHistaminergic: Sedation, Wt gain
• Anticholinergic: PerAnticholinergic: Periipheral & Centralpheral & Central• Alpha-Adrenergic: Orthostasis, EKGAlpha-Adrenergic: Orthostasis, EKG• Endocrine-Sexual: PRL, 5-HTEndocrine-Sexual: PRL, 5-HT• HHaaematologic: Agranulocytosisematologic: Agranulocytosis• Eye & Skin: retinopathy, photosensitivityEye & Skin: retinopathy, photosensitivity• Seizure threshold: loweredSeizure threshold: lowered• Liver: cholestatic jaundice Liver: cholestatic jaundice (chlorpromazine)(chlorpromazine)
tuberoinfundibulardopaminergic
blockade
nigrostriataldopaminergic
blockade
clozapine
Duration of antipsychotic treatment
• After first episode of psychosis: 1-2 years
• After second episode of psychosis: 5 years
• After 3 episodes: > 5 years
Schizophrenia: Acute phase, remission, relapse
20 30 40 50 60 70roky
M E D I K A C E
Symptoms in relapse
Pathophysiological processses
– asymptomatic during remision
Medication knowledge in the context of the disease
Medication
Medication
Antipsychotics: Summary
• Regulate dopamine
• Reduce hallucinations, delusions, improve cognitive functions, etc
• Prevent relapse
75 %one year relapse rate without medication
15 % one year relapse rate on medication
Howevher….Treatment noncompliance!!!!
10 days 6 months 12 months 24 months
25%
33%
40%
76%
69%
discharge
noncompliance(%)
Perkins, 2002; Kamali et al., 2006, Lam et al, 2002; Weiden et al., 1997
+
C
6 months
Reasons for non-compliance
Relapse prevention
Vulnerability factorsInformation processing deficitsAutonomic reaction anomalies
Social competence and coping limitations
Social Environmental Stress:Critical comments, overinvolvement
Chaotic family environmentStigma
Relapse
Enhance coping skillsMedication
Cognitive rehabilitationSupportive psychotherapy
PsychoeducationSocial skills training
Remove stressorsFamily interventionDestigmatization
Integrated therapy of schizophrenia
Phases of the illnessThe goal of the intervention
Pharmacotherapy Psychosocial inteventions
services
Prodroms Early diagnostics Only as an experiment
Keep in contact Outpatient services
Acute phase(First episode or relapse)
Treat psychotic symptoms Therapeutic relationship
Pharmacotherapy
Antipsychotics+Anxiolytics+hypnotics
Start therapeutic relationship
Structured communication
Avoid stress
hospitalization
Stabilization phase Remission Pharmacoherapy with special attention to side effects
Supportive psychotherapyPsychoeducation(patient +family)
Day care clinic, outpatient department
Stable phase (remission)
Relapse prevention Pharmacotherapy Social skills trainingCognitive rehabilitation
Community care, day care clinic, outpatient department
Lack of information about disease
Basic psychoeducation
Basic psychoeducation
Lifestyle improvement
Lifestyle improvement
Family psychoeducation
Family psychoeducation
Psychoeducation: What is it?
• Systematic, structured, didactic information on the illness and its treatment, which includes integrating emotional aspects in order to enable the participants to cope with the illness
Bauml et al.,2003
Extrapyramidal Sx. (EPS)Extrapyramidal Sx. (EPS)
• Acute DystoniasAcute Dystonias
• Antipsychotic-induced Parkinsonism Antipsychotic-induced Parkinsonism
• AkathisiaAkathisia
• Tardive Dyskinesia (TD)Tardive Dyskinesia (TD)
• Neuroleptic Malignat Syndrome (NMS)Neuroleptic Malignat Syndrome (NMS)
Acute DystoniasAcute Dystonias
• Muscle spasm face-neck-trunk-eye-larinxMuscle spasm face-neck-trunk-eye-larinx• Early in Tx., young malesEarly in Tx., young males• Dose Related, Tolerance, incidence 50%Dose Related, Tolerance, incidence 50%• Treatment:Treatment: biperiden 2,5-5 mg IM or IV (slowly); biperiden 2,5-5 mg IM or IV (slowly);
Benadryl 50 mg IM (IV 25-50 for laryngospasm), Benadryl 50 mg IM (IV 25-50 for laryngospasm), Cogentin 1-4 mg IM Cogentin 1-4 mg IM
• Prevention reduces incidence to 5% Prevention reduces incidence to 5% – Low dose, Low dose, – Benztropine 1 mg / every Haldol 5 mgBenztropine 1 mg / every Haldol 5 mg
Antipsychotic-induced Antipsychotic-induced ParkinsonismParkinsonism
• Incidence 50-75% with high pot.Incidence 50-75% with high pot.• RigidityRigidity• Bradikinesia: mask face-gait problemsBradikinesia: mask face-gait problems• Resting TremorResting Tremor• Flexed PostureFlexed Posture• Dif Dx. with flat affectDif Dx. with flat affect• Tx: Cogentin, Artane 2 mg bid-tid (elder)Tx: Cogentin, Artane 2 mg bid-tid (elder)
– Reduces incidence to 5-10%Reduces incidence to 5-10%
AkathisiaAkathisia
• Subjective feeling of restlesnessSubjective feeling of restlesness• Unable to sit still, pacingUnable to sit still, pacing• Incidence 20-30%, lower with low doseIncidence 20-30%, lower with low dose• Dif Dx.: psychosis, agitation, anxietyDif Dx.: psychosis, agitation, anxiety• Tx: Tx: lower the antipsychotic dose if possible, lower the antipsychotic dose if possible,
Propranolol 30-90 mg/d (not in asthma or Propranolol 30-90 mg/d (not in asthma or diabetes), Klonopin 1 mg biddiabetes), Klonopin 1 mg bid
• SSRI Antidepressants cause akathisia tooSSRI Antidepressants cause akathisia too
Tardive Dyskinesia (TD)Tardive Dyskinesia (TD)
• Slow choreo-athetotic movementsSlow choreo-athetotic movements
• Oro-facial musclesOro-facial muscles
• Risk 4% per year of exposureRisk 4% per year of exposure– Risk factors elderly women, mood DO, Risk factors elderly women, mood DO,
diab.diab.
• Risk managementRisk management– document informed consent, AIMS Testsdocument informed consent, AIMS Tests
• Tx?: Vit E 1600 U/d, Clozapine low riskTx?: Vit E 1600 U/d, Clozapine low risk
Neuroleptic Malignant Neuroleptic Malignant Syndrome (NMS)Syndrome (NMS)
• Medical Emerg, mort. 20% (now 4%)Medical Emerg, mort. 20% (now 4%)• 1. Fever1. Fever >100.4F / 37.5C >100.4F / 37.5C• 2. Severe EPS2. Severe EPS: lead-pipe/cogwheel : lead-pipe/cogwheel
rigidity, sialorrhea, oculogyric crisisrigidity, sialorrhea, oculogyric crisis• 3. Autonomic DysFx3. Autonomic DysFx: BP fluctuations, : BP fluctuations,
tachycardia, tachypnea, diaphoresistachycardia, tachypnea, diaphoresis• Also: Alt. conciousness, delirium, Also: Alt. conciousness, delirium,
leukocytosis (>15.000 WBC), CPK > 300, leukocytosis (>15.000 WBC), CPK > 300, seizures, arrseizures, arryythmias, mthmias, myyoglobinuria, ARFoglobinuria, ARF
NMSNMS
• Incidence 0.1-1%, (60% of it in 1st 2 Incidence 0.1-1%, (60% of it in 1st 2 wks)wks)
• Risk factors: multiple IM injections, Risk factors: multiple IM injections, high dose, rapid increase of dose high dose, rapid increase of dose agitation, dehydration, heat, lithium useagitation, dehydration, heat, lithium use
• Tx: STOP ALL antipsychotics, also Tx: STOP ALL antipsychotics, also antiemetic Reglan (Metoclopramide), antiemetic Reglan (Metoclopramide), antidepr. Amoxapineantidepr. Amoxapine
NMS TreatmentNMS Treatment
• Stop ALL AntipsychoticsStop ALL Antipsychotics• Dif. Dx: fever & deliriumDif. Dx: fever & delirium• Dantrolene (muscle relax) 1-3 mg/kg/day Dantrolene (muscle relax) 1-3 mg/kg/day
NTE 10 mg/kg/dNTE 10 mg/kg/d• Bromocriptine (DA Agonist) 5 mg tid-qidBromocriptine (DA Agonist) 5 mg tid-qid• Supportive Tx:Supportive Tx:
– IV fluids, antipyretics, cooling blankets, IV fluids, antipyretics, cooling blankets, close cardiac & renal monitoringclose cardiac & renal monitoring
Clozapine [Clozaril]Clozapine [Clozaril]
• Weak D1=D2 block, high 5-HT2 blockWeak D1=D2 block, high 5-HT2 block– (5-HT2/D2 = 20/1)(5-HT2/D2 = 20/1)
• alpha1, alpha2, H1, M1alpha1, alpha2, H1, M1
• Tx Res. Schizophrenia, mood stabilizerTx Res. Schizophrenia, mood stabilizer
• Effective in Negative and Positive Sx, Effective in Negative and Positive Sx, low EPS, low TDlow EPS, low TD
Clozapine: Side EffectsClozapine: Side Effects
• Agranulocytosis (1%), 80% in 1st 4.5 Agranulocytosis (1%), 80% in 1st 4.5 mo.mo.
• If WBC<3,000 and ANC<1,500 stop, wait If WBC<3,000 and ANC<1,500 stop, wait until it returns to 3,500 CBC bi-wkuntil it returns to 3,500 CBC bi-wk
• If WBC<2,000 and ANC<1,000 stop & do If WBC<2,000 and ANC<1,000 stop & do not re-startnot re-start
• Do not use with Carbamazepine or Do not use with Carbamazepine or other bone marrow suppressorsother bone marrow suppressors